Patented PDE10A inhibitors: Novel compounds since 2007

Expert Opinion on Therapeutic Patents

Volumn 19, Issue 12, 2009, Pages 1715-1725

  Kehler, Jan ^a   Kilburn, John Paul ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

Antipsychotic; Basal ganglia; Huntingtons disease; Medium spiny neuron; Negative symptom; PDE10A; Phosphodiesterase 10A; Pro cognitive; Schizophrenia; Striatum

Indexed keywords

2 [4 [1 METHYL 4 (4 PYRIDINYL) 3 PYRAZOLYL]PHENOXYMETHYL]QUINOLINE; COMPOUND 19; COMPOUND 21; COMPOUND 22; COMPOUND 23; COMPOUND 24; COMPOUND 25; COMPOUND 26; COMPOUND 27; COMPOUND 28; COMPOUND 29; N (5 BENZAMIDO 4 OXO 6 PHENYLHEXANOYL)PROLINE; PHOSPHODIESTERASE 10A INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PLACEBO; TOFISOPAM; TP 10; UNCLASSIFIED DRUG;

CHEMISTRY; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; HUMAN; IC 50; NEGATIVE SYNDROME; NONHUMAN; PATENT; POSITIVE SYNDROME; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PATENTS AS TOPIC; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; SCHIZOPHRENIA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 71449127163     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543770903431050     Document Type: Review

References (53)

1. Soderling SH, Bayuga SJ, Beavo JA, et al. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc Natl Acad Sci USA 1999;96(12):7071-7076
2. Fujishige K, Kotera J, Michibata H, et al. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem 1999;274(26):18438-18445
3. Loughney K, Snyder PB, Uher L. Isolation and characterization of PDE10A, a novel human 3¢, 5¢-cyclic nucleotide phosphodiesterase. Gene 1999;234(1):109-117
4. Coskran TM, Morton D, Menniti FS et al. Immuno-histochemical localization of phosphodiesterase 10A in multiple mammalian species. J Histochem Cytochem 2006;54(11):1205-1213
5. Hebb AL, Robertson HA, Denovan-Wright EM, et al. Striatal phosphodiesterase mRNA and protein levels are reduced in huntington's disease transgenic mice prior to the onset of motor symptoms. Neuroscience 2004;123(4):967-981
6. Giampà C, Patassini S, Borreca A, et al. Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of huntington's disease. Neurobiol Dis 2009;34(3):450-456
7. Siuciak JA, Chapin DS, Harms JF. Inhibition of the striatum-enriched phosphodiesterase PDE10A: A novel approach to the treatment of psychosis. Neuropharmacology 2006;51(2):386-396
8. Siuciak JA, McCarthy SA, Chapin DS, et al. Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: Evidence for altered striatal function. Neuropharmacology 2006;51(2):374-385
9. Menniti FS, Chappie TA, Humphrey JM, et al. Phosphodiesterase 10A inhibitors: A novel approach to the treatment of the symptoms of schizophrenia. Curr Opin Invest Drugs 2007;8(1):54-59
10. Schmidt CJ, Chapin DS, Cianfrogna J, et al. Preclinical characterization of selective phosphodiesterase 10A inhibitors: A new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 2008;325(2):681-690
11. Weber M, Breier M, Ko D, et al. Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine. Psychopharmacology 2009;203(4):723-735
12. Siuciak JA. The role of phosphodiesterases in schizophrenia. CNS Drugs 2008;22(12):983-993
13. Grauer SM, Pulito VL, Navarra RL, et al. PDE10A inhibitor activity in preclinical models of the positive, cognitive and negative symptoms of schizophrenia. J Pharmacol Exp Ther 2009; DOI:10.1124/jpet.109.155994
14. Chappie T, Humphrey J, Menniti F, et al. PDE10A inhibitors: An assessment of the current CNS drug discovery landscape. Curr Opin Drug Discov Devel 2009;12(4):458-467
15. Wang H, Liu Y, Hou J, et al. Structural insight into substrate specificity of phosphodiesterase. Proc Natl Acad Sci USA 2007;104(14):5782-5787
16. Card GL, England BP, Suzuki Y, et al. Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure (Cambridge) 2004;12:2233-2247
17. Manallack DT, Hughes RA, Thompson PE. The next generation of phosphodiesterase inhibitors: Structural clues to ligand and substrate selectivity of phosphodiesterases. J Med Chem 2005;48:3449-3462
18. Gross-Langenhoff M, Hofbauer K, Weber J, et al. cAMP is a ligand for the tandem GAF domain of human phosphodiesterase 10 and cGMP for the tandem GAF domain of phosphodiesterase. J Biol Chem 2006;281(5):2841-2846
19. Handa N, Mizohata E, Kishishita S, et al. Crystal structure of the GAF-B domain from human phosphodiesterase 10A complexed with its ligand, cAMP. J Biol Chem 2008;283(28):19657-19664
20. Chappie TA, Humphrey JM, Allen MP, et al. Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors. J Med Chem 2007;50(2):182-185
21. Verhoest PR, Chapin DS, Corman M, et al. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-Methyl-4-pyridin-4-yl-1Hpyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. J Med Chem 2009;52(16):5188- 5196
22. F.Hoffmann-LA. ROCHE AGWO 2009/ 090004; 2009
23. Wadenberg MLG, Hicks PB. The conditioned avoidance response test re-evaluated: Is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev 1999;23(6):851-862
24. Sano H, Nagai Y, Miyakawa T, et al. Increased social interaction in mice deficient of the striatal medium spiny neuron-specific phosphodiesterase 10A2. J Neurochem 2008;105(2):546-556
25. Elbion AG. WO-2007137819; 2007
26. Elbion AG. WO-2007137820; 2007
27. Wyeth/Elbion AG. WO 2009/068246; 2009
28. Elbion AG. WO 2009/068320; 2009
29. Wyeth/Elbion AG. WO 2009/070583; 2009
30. Wyeth/Elbion AG. WO 2009/070584;2009
31. Malamas MS, Hoefgen N, Stange H, et al. Potent and selective hPDE10A inhibitors for the treatment of schizophrenia. Abstracts of Papers, 238th ACS National Meeting, Washington, DC, United States, August 16-20; 2009, MEDI-021
32. Pfizer, Inc. WO2007085954; 2007
33. Pfizer, Inc. WO2007096743; 2007
34. Pfizer, Inc. WO2008020302; 2008
35. Pfizer, Inc. US20070155779; 2007
36. Pfizer, Inc. WO2008001182; 2008
37. Pfizer, Inc. WO2008004117; 2008
38. Pfizer, Inc. WO2008084299; 2008
39. H Lundbeck A/S. WO2007082546; 2007
40. H Lundbeck A/S. WO2008006372; 2008
41. H Lundbeck A/S. WO2009036766; 2009
42. Amgen Inc; Memory Pharmaceuticals Corp. WO2007022280; 2007
43. Amgen Inc; Memory Pharmaceuticals Corp. WO2007098169; 2007
44. Amgen Inc; Memory Pharmaceuticals Corp. WO2007098214; 2007
45. Amgen Inc; Memory Pharmaceuticals Corp. WO2007100880; 2007
46. Amgen Inc; Memory Pharmaceuticals Corp. WO2007103554; 2007
47. Amgen Inc; Memory Pharmaceuticals Corp. WO2007103370; 2007
48. Amgen Inc; Memory Pharmaceuticals Corp. WO2007103260; 2007
49. Amgen Inc; Memory Pharmaceuticals Corp. WO2009025823 and WO2009025839; 2009
50. Amgen Inc; Memory Pharmaceuticals Corp. WO2009029214; 2009
51. Matrix Laboratories Ltd. WO2008032171; 2008
52. Omeros Corp. WO2008064342; 2008
53. OmerOs Corp101. US20080300240;2008